scholarly journals Combining synthetic carbohydrate vaccines with cancer cell glycoengineering for effective cancer immunotherapy

2012 ◽  
Vol 61 (11) ◽  
pp. 2045-2054 ◽  
Author(s):  
Lei Qiu ◽  
Xi Gong ◽  
Qianli Wang ◽  
Jie Li ◽  
Honggang Hu ◽  
...  
Nano Letters ◽  
2021 ◽  
Author(s):  
Xiang Xiong ◽  
Jingya Zhao ◽  
Jingmei Pan ◽  
Chunping Liu ◽  
Xing Guo ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1757 ◽  
Author(s):  
Elisabet Cuyàs ◽  
Sara Verdura ◽  
Begoña Martin-Castillo ◽  
Tomás Alarcón ◽  
Ruth Lupu ◽  
...  

One of the greatest challenges in the cancer immunotherapy field is the need to biologically rationalize and broaden the clinical utility of immune checkpoint inhibitors (ICIs). The balance between metabolism and immune response has critical implications for overcoming the major weaknesses of ICIs, including their lack of universality and durability. The last decade has seen tremendous advances in understanding how the immune system’s ability to kill tumor cells requires the conspicuous metabolic specialization of T-cells. We have learned that cancer cell-associated metabolic activities trigger shifts in the abundance of some metabolites with immunosuppressory roles in the tumor microenvironment. Yet very little is known about the tumor cell-intrinsic metabolic traits that control the immune checkpoint contexture in cancer cells. Likewise, we lack a comprehensive understanding of how systemic metabolic perturbations in response to dietary interventions can reprogram the immune checkpoint landscape of tumor cells. We here review state-of-the-art molecular- and functional-level interrogation approaches to uncover how cell-autonomous metabolic traits and diet-mediated changes in nutrient availability and utilization might delineate new cancer cell-intrinsic metabolic dependencies of tumor immunogenicity. We propose that clinical monitoring and in-depth molecular evaluation of the cancer cell-intrinsic metabolic traits involved in primary, adaptive, and acquired resistance to cancer immunotherapy can provide the basis for improvements in therapeutic responses to ICIs. Overall, these approaches might guide the use of metabolic therapeutics and dietary approaches as novel strategies to broaden the spectrum of cancer patients and indications that can be effectively treated with ICI-based cancer immunotherapy.


2014 ◽  
Vol 2 (S3) ◽  
Author(s):  
Gitte Holmen Olofsson ◽  
Manja Idorn ◽  
Wajid Khan ◽  
Mads Hald Andersen ◽  
Bernhard Moser ◽  
...  

2016 ◽  
Vol 29 (7) ◽  
pp. 1603239 ◽  
Author(s):  
Flavia Fontana ◽  
Mohammad-Ali Shahbazi ◽  
Dongfei Liu ◽  
Hongbo Zhang ◽  
Ermei Mäkilä ◽  
...  

2020 ◽  
Vol 33 (1) ◽  
pp. 17-26
Author(s):  
Alok Kumar ◽  
Kenji Chamoto

Abstract Energy metabolism plays an important role in proliferating cells. Recent reports indicate that metabolic regulation or metabolic products can control immune cell differentiation, fate and reactions. Cancer immunotherapy based on blockade of programmed cell death protein 1 (PD-1) has been used worldwide, but a significant fraction of patients remain unresponsive. Therefore, clarifying the mechanisms and overcoming the unresponsiveness are urgent issues. Because cancer immunity consists of interactions between the cancer and host immune cells, there has recently been a focus on the metabolic interactions and/or competition between the tumor and the immune system to address these issues. Cancer cells render their microenvironment immunosuppressive, driving T-cell dysfunction or exhaustion, which is advantageous for cancer cell survival. However, accumulating mechanistic evidence of T-cell and cancer cell metabolism has gradually revealed that controlling the metabolic pathways of either type of cell can overcome T-cell dysfunction and reprogram the metabolic balance in the tumor microenvironment. Here, we summarize the role of immune metabolism in T-cell-based immune surveillance and cancer immune escape. This new concept has boosted the development of combination therapy and predictive biomarkers in cancer immunotherapy with immune checkpoint inhibitors.


Sign in / Sign up

Export Citation Format

Share Document